Get a free sample of Pulmonary Fibrosis Biomarkers Market
Thank you!
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Pulmonary Fibrosis Biomarkers Market
Thank you!
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Pulmonary Fibrosis Biomarkers Market Size
Pulmonary Fibrosis Biomarkers Market size was valued at around USD 4.1 billion in 2023 and is estimated to reach over USD 6 billion by 2032. Pulmonary fibrosis biomarkers are specific molecules, substances, or characteristics found in biological samples such as blood, sputum, or lung tissue that provide valuable information about the presence, severity, progression, or response to treatment of pulmonary fibrosis.
The increasing advancements in biomarker discovery technology is a significant driver for the market. For instance, according to the Prognostic Lung Fibrosis Consortium (PROLIFIC), in 2023, the identification of 12 potential prognostic, blood-based protein biomarkers helped predict the pulmonary fibrosis patient’s specific and selective requirement about the treatment regimen. This allows for the precision medicine approach and tailor treatment strategies to individuals based on their unique biomarker profiles.
Furthermore, market growth is attributed to multiple factors, including the rising prevalence of pulmonary fibrosis, growing government initiatives and policies, rising use of biomarkers, and increasing research and development in the multi-omics sector (which is estimated to reach 12.2 billion by 2032.
Who are the key leaders in the pulmonary fibrosis biomarkers industry?
Biocartis NV, Biogen Inc, Bristol-Myers Squibb Company, F. Hoffman-La Roche Ltd, Galapagos NV, Lung Therapeutics, Inc., Myriad Genetics, Inc, OptiKira LLC, Respivant Sciences GmbH, and Veracyte, Inc , are some of the major pulmonary fibrosis biomarkers companies worldwide.
How big is the North America pulmonary fibrosis biomarkers market?
North America pulmonary fibrosis biomarkers industry recorded USD 1.7 billion in 2023 due to the presence of a highly advanced healthcare infrastructure with well-established hospitals, research institutions, and diagnostic laboratories in the region.
Why is the use of pulmonary fibrosis biomarkers in imaging tests growing?
The imaging test segment recorded USD 1.7 billion in 2023 and is expected to register an appreciable CAGR from 2024-2032 due to imaging tests complementing biomarker analysis and providing a comprehensive view of disease status.
What is the size of the pulmonary fibrosis biomarkers industry?
Pulmonary fibrosis biomarkers market size was USD 4.1 billion in 2023 and is expected to reach over USD 6 billion by 2032 owing to the increasing advancements in biomarker discovery technology worldwide.